Articles from Aerovate Therapeutics, Inc.
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · July 8, 2024
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · June 17, 2024
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
Baseline characteristics reflect a PAH population with significant disease
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · May 21, 2024
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended March 31, 2024, and recent business highlights.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · May 13, 2024
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced an upcoming poster presentation at the 2024 American Thoracic Society (ATS) International Conference taking place May 17-22, 2024, in San Diego, CA. The presentation will provide baseline characteristics from patients enrolled in the dose-ranging Phase 2b portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT), a Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multi-national trial evaluating the safety and efficacy of AV-101 in adults with pulmonary arterial hypertension.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · March 27, 2024
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the year ended December 31, 2023, and recent business highlights.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · March 25, 2024
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease, today announced that its Board of Directors has elected current Board member, Habib Dable, as Chair of the Board. Mr. Dable succeeds Mark Iwicki, who will continue to serve on the Board.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · March 6, 2024
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
Topline Phase 2b data expected in June 2024
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · November 20, 2023
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended September 30, 2023, and recent business highlights.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · November 13, 2023
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended June 30, 2023, and recent business highlights.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · August 14, 2023
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Habib Dable as a member of Aerovate’s Board of Directors. Mr. Dable is the former President and Chief Executive Officer of Acceleron Pharma Inc. and brings nearly three decades of experience working with emerging biotech and big pharma companies.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · July 11, 2023
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary diseases, today announced that Company management will present at the Jefferies Global Healthcare Conference on Wednesday, June 7, at 8:00 a.m. ET, which presentation will include an overview of AV-101 and the IMPAHCT Phase 2b/Phase 3 trial.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · June 1, 2023
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · May 22, 2023
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended March 31, 2023, and recent business highlights.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · May 15, 2023
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the year ended December 31, 2022, and recent business highlights.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · March 29, 2023
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced that Company management will participate in a panel discussion at the Cowen 43rd Annual Health Care Conference on Wednesday, March 8, at 10:30 a.m. ET. The panel discussion will focus on respiratory diseases, including pulmonary arterial hypertension (PAH), the recent sotatercept phase 3 data, and an overview of AV-101 and the IMPAHCT Phase 2b/Phase 3 trial.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · March 2, 2023
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the appointment of Donald Santel as a member of Aerovate’s Board of Directors. With over 40 years of working in the industry, Mr. Santel brings to Aerovate extensive experience in building successful pharmaceutical companies.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · January 23, 2023
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · November 17, 2022
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for the quarter ended September 30, 2022, and recent business highlights.
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · November 14, 2022
![](https://ml.globenewswire.com/media/5fe89d51-5e46-4a1e-945c-a257c81b0d95/small/aerovate-logo-horizontal-png.png)
Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigor
By Aerovate Therapeutics, Inc. · Via GlobeNewswire · October 18, 2022